Survival Outcomes of Calcium Channel Blocker Therapy in Patients With Non-Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor Inhibitors: A Retrospective Study

被引：2
作者：
Hsieh, Hui-Hsia [1 ,2 ]
Wu, Tien-Yuan [1 ,3 ]
Chen, Chi-Hua [1 ]
Kuo, Yu-Hung [4 ]
Hour, Mann-Jen [2 ,5 ]
机构：
[1] Taichung Tzu Chi Hosp, Buddhist Tzu Chi Med Fdn, Dept Pharm, Taichung, Taiwan
[2] China Med Univ, Sch Pharm, Taichung, Taiwan
[3] Tzu Chi Univ, Grad Inst Clin Pharm, Hualien, Taiwan
[4] Taichung Tzu Chi Hosp, Buddhist Tzu Chi Med Fdn, Dept Res, Taichung, Taiwan
[5] China Med Univ, Sch Pharm, 100,Sec 1,Jingmao Rd, Taichung 406040, Taiwan
来源：
INTEGRATIVE CANCER THERAPIES | 2023年 / 22卷
关键词：
epidermal growth factor receptor tyrosine kinase inhibitors; calcium channel blockers; non-small cell lung cancer; targeted therapy; cancer therapy; CLINICAL IMPACT; ERLOTINIB; NSCLC;
D O I：
10.1177/15347354231178903
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background:Non-cancer drugs are currently being repurposed for cancer treatment. Mounting evidence highlights the influence of calcium channels on tumorigenesis and progression. Hence, inhibition of calcium signaling may be a promising cancer treatment strategy. Objective:In this study, we aimed to examine whether calcium channel blockers (CCBs) affect the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in patients with non-small cell lung cancer (NSCLC). Design:We conducted a retrospective analysis. Methods:In this study, conducted between January 2009 and June 2021, patients with NSCLC treated with erlotinib, or gefitinib for at least 1 week were enrolled and divided into 2 groups: CCBs-/EGFR-TKIs+ and CCBs+/EGFR-TKIs+, depending on whether they received CCB therapy. Progression-free survival (PFS) and overall survival (OS) were determined as the primary and secondary endpoints, respectively. Results: The estimated median PFS and OS for the CCBs-/EGFR-TKIs+group were 7.70 and 12.17 months, respectively, and they were significantly different from those of the CCBs+/EGFR-TKIs+ group (10.43 and 18.07 months, respectively). CCB use was associated with improved PFS (adjusted hazard ratios [HR] 0.77, 95% confidence interval [CI]: 0.61-0.98; P = .035) and OS (adjusted HR 0.66, 95% CI: 0.51-0.84; P < .001). Conclusion:Calcium channels have been implicated in cancer pathogenesis. Our findings revealed the potential additive anticancer effects of CCBs when used concomitantly with EGFR-TKIs. However, study limitations, including the retrospective nature and small number of patients, necessitate large-scale prospective studies on the therapeutic potential of CCB as an adjunctive therapy with EGFR-TKIs in patients with NSCLC.
引用
收藏
页数：9
相关论文
共 50 条
[31]   Relationship between Epidermal Growth Factor Receptor Mutations and Adverse Events in Non-Small Cell Lung Cancer Patients treated with Afatinib [J].
Yamashita, Sayaka ;
Tanaka, Hiroaki ;
Tatsumichi, Takakiyo ;
Yamaguchi, Kazunori ;
Tai, Tatsuya ;
Suzuki, Kiyo ;
Motoki, Takahiro ;
Houchi, Hitoshi ;
Kosaka, Shinji .
JOURNAL OF MEDICAL INVESTIGATION, 2021, 68 (1-2) :125-128
[32]   Epidermal Growth Factor Receptor Mutation Status and the Impact on Clinical Outcomes in Patients with Non-Small Cell Lung Cancer [J].
Huang, H. M. ;
Wei, Y. ;
Wang, J. J. ;
Ran, F. Y. ;
Wen, Y. ;
Chen, Q. H. ;
Zhang, B. F. .
BALKAN JOURNAL OF MEDICAL GENETICS, 2022, 25 (02) :29-36
[33]   Clinical impact of tetracyclines and/or proton pump inhibitors on the efficacy of epidermal growth factor receptor inhibitors in non-small cell lung cancer: a retrospective cohort study [J].
Hsieh, Hui-Hsia ;
Wu, Tien-Yuan ;
Chen, Chi-Hua ;
Kuo, Yu-Hung ;
Hour, Mann-Jen .
BMC CANCER, 2023, 23 (01)
[34]   Clinical impact of tetracyclines and/or proton pump inhibitors on the efficacy of epidermal growth factor receptor inhibitors in non-small cell lung cancer: a retrospective cohort study [J].
Hui-Hsia Hsieh ;
Tien-Yuan Wu ;
Chi-Hua Chen ;
Yu-Hung Kuo ;
Mann-Jen Hour .
BMC Cancer, 23
[35]   Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay [J].
Marileila Varella-Garcia .
Diagnostic Pathology, 1
[36]   Targeted therapy in non-small cell lung cancer: a focus on epidermal growth factor receptor mutations [J].
Milano, Gerard A. .
CHINESE CLINICAL ONCOLOGY, 2015, 4 (04)
[37]   Neutrophil to Lymphocyte Ratio as a Prognostic Factor in European Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors [J].
Aguiar-Bujanda, David ;
Duenas-Comino, Arancha ;
Saura-Grau, Salvador ;
Ros-Sanjuan, Laura ;
Blanco-Sanchez, Maria J. ;
Hernandez-Sosa, Maria ;
Mori-De Santiago, Marta ;
Galvan-Ruiz, Saray ;
Lorenzo-Barreto, Jose E. ;
Vargas-Prado, Ana M. ;
Bohn-Sarmiento, Uriel .
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 (12) :755-760
[38]   Small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer [J].
Cascone, T ;
Morelli, MP ;
Ciardiello, F .
ANNALS OF ONCOLOGY, 2006, 17 :46-48
[39]   Translational Research on Epidermal Growth Factor Receptor Gene Mutations in Targeted Therapy for Patients with Advanced Non-Small Cell Lung Cancer [J].
Wang Xiao-yan ;
Zhou Er-xi .
JOURNAL OF INTERNATIONAL TRANSLATIONAL MEDICINE, 2015, 3 (04) :248-252
[40]   Activity of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients with Non-small Cell Lung Cancer Harboring Rare Epidermal Growth Factor Receptor Mutations [J].
De Pas, Tommaso ;
Toffalorio, Francesca ;
Manzotti, Michela ;
Fumagalli, Caterina ;
Spitaleri, Gianluca ;
Catania, Chiara ;
Delmonte, Angelo ;
Giovannini, Monica ;
Spaggiari, Lorenzo ;
de Braud, Filippo ;
Barberis, Massimo .
JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (11) :1895-1901
12345